Roy S. Herbst, MD, PhD
机构: Yale School of Medicine | Yale Cancer Center | Smilow Cancer Hospital at Yale-New Haven
每年引用次数
引用次数
引用: 105,712
H-指数: 146
I10-指数 : 487
出版物: 998
Phase III trial of gefitinib versus docetaxel in patients with previously treated advanced non-small-cell lung cancer
Roy S. Herbst , Latha Shivakumar , David R. Gandara , Corey J. Langer
Clinical Lung Cancer 8 ( 9) 527 -528
2007
Antiangiogenesis in the treatment of NSCLC. Part 2 of a 3-part series: Targeting VEGF - Current and future research directions
Roy S. Herbst , David H. Johnson , Alan B. Sandler
Clinical advances in hematology & oncology 3
2005
Addition of thalidomide to chemotherapy does not improve efficacy of carboplatin/etoposide in small-cell lung cancer: Phase III results
Roy S. Herbst , Latha Shivakumar , David R. Gandara , Corey J. Langer
Clinical Lung Cancer 8 ( 9)
2007
ZD6474, a small molecule targeting VEGF and EGF receptor signaling, inhibits lung angiogenesis and metastasis and improves survival in an orthotopic model of non-small cell lung cancer
Roy S. Herbst , Wenjuan Wu , Robert R. Langley , Tomoaki Shintani
Cancer Research 64 1051 -1051
11
2004
Biology and therapy of human small cell lung cancer (SCLC) in novel orthotopic nude mouse models
Roy S. Herbst , Wenjuan Wu , Waun K. Hong , Tomoaki Shintani
Cancer Research 64 1185 -1185
2004
A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): Interim safety and clinical activity in patients with urothelial carcinoma.
Daniel Peter Petrylak , Hendrik-Tobias Arkenau , Jose Luis Perez-Gracia , Matthew Krebs
Journal of Clinical Oncology 35 349 -349
19
2017
A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer.
Mark A. Socinski , Joachim Von Pawel , Kazuo Kasahara , Igor Bondarenko
Journal of Clinical Oncology 36 109 -109
3
2018
Multiplexed analysis of myeloid cell (MC) markers to characterize the innate immune composition and clinical features of human non-small cell lung carcinomas (NSCLC).
Brian S. Henick , Ila Datar , Franz Villarroel-Espindola , Miguel F. Sanmamed
Journal of Clinical Oncology 36 12002 -12002
2018
Expression and clinical significance of antigen presentation components beta-2 microglobulin, HLA class I heavy chains, and HLA class II in non-small cell lung cancer (NSCLC).
Ila Datar , Franz Villarroel-Espindola , Brian S. Henick , Konstantinos N. Syrigos
Journal of Clinical Oncology 36 12015 -12015
1
2018
Objective measurement and significance of PD-L1, B7-H3, B7-H4 and TILs in small cell lung cancer (SCLC).
Kurt Alex Schalper , Daniel E. Carvajal-Hausdorf , Joseph Francis McLaughlin , Mehmet Altan
Journal of Clinical Oncology 34 8566 -8566
5
2016
Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010.
Edward B. Garon , Roy S. Herbst , Dong-Wan Kim , Enriqueta Felip
Journal of Clinical Oncology 34 9024 -9024
10
2016
Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors.
Scott N. Gettinger , Xuchen Zhang , Robert Homer , Jennifer Possick
Journal of Clinical Oncology 34 9030 -9030
5
2016
Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–Positive NSCLC.
Paul Baas , Edward B. Garon , Roy S. Herbst , Enriqueta Felip
Journal of Clinical Oncology 34 9015 -9015
9
2016
Measurement of spatial and antibody-based PD-L1 heterogeneity in non-small cell lung cancer.
Patricia Gaule , Jamaal Rehman , James William Smithy , Maria Toki
Journal of Clinical Oncology 34 9040 -9040
2
2016
HER2 amplification in EGFR mutant NSCLC after acquired resistance (AR) to EGFR-directed therapies.
Bing Xia , Anna Wurtz , Scott N. Gettinger , Roy S. Herbst
Journal of Clinical Oncology 34 ( 15_suppl) 9049 -9049
1
2016
Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, demographics, and molecular markers.
Vassiliki Papadimitrakopoulou , Mary Redman , David R. Gandara , Fred R. Hirsch
Journal of Clinical Oncology 34 ( 15_suppl) 9088 -9088
2016
Outcomes for patients treated with or without bevacizumab on SWOG S0819: A randomized, phase III study comparing carboplatin/Paclitaxel or carboplatin/Paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC).
Thomas John Semrad , Mary Weber Redman , Roy S. Herbst , Edward S. Kim
Journal of Clinical Oncology 34 ( 15_suppl) 9082 -9082
4
2016
Biomarker-enriched efficacy of cetuximab-based therapy: Squamous subset analysis from S0819, a phase III trial of chemotherapy with or without cetuximab in advanced NSCLC.
Susanne M. Arnold , Marileila Varella-Garcia , James Moon , Philip C. Mack
Journal of Clinical Oncology 34 ( 15_suppl) 9090 -9090
4
2016
Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P).
Ian Chau , Johanna C. Bendell , Emiliano Calvo , Rafael Santana-Davila
Journal of Clinical Oncology 35 102 -102
18
2017
Measurement of PD-1, TIM-3 and LAG-3 protein in non-small cell lung carcinomas (NSCLCs) with acquired resistance to PD-1 axis blockers.
Ila Datar , Nikita Mani , Brian S. Henick , Anna Wurtz
Journal of Clinical Oncology 35
3
2017